ESPERITE (ESP) financial results for 2016 published

May 23, 2017 Financial Reports

ESPERITE N.V. (Euronext: ESP, “Esperite” or “the Group”) has published today its Annual Report for the year ended 31 December 2016. The 2016 Annual Report is now available on the Company’s website www.esperite.com.

  • CryoSave’s EBITDA improved from € -2.5 million to € -0.7 million.
  • Genoma’s autonomous revenue increased by 80% up to a level of € 6.9 million.
  • Esperite’s consolidated revenue decreased by 4.5% to € 26.3 million.
  • Consolidated revenues were lower than expected but the gross margin is stable and gross profit increased by 2.3%.

Zutphen, the Netherlands – 23 May 2017

read more

Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies

March 8, 2017 Financial Reports

Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies

Total investment can reach EUR 13 million upon exercise of share subscription warrants

Zutphen, The Netherlands – 08 March 2017

read more

Page 1 of 712345...Last »